GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Current Ratio

InnoCare Pharma (HKSE:09969) Current Ratio : 4.19 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. InnoCare Pharma's current ratio for the quarter that ended in Dec. 2023 was 4.19.

InnoCare Pharma has a current ratio of 4.19. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for InnoCare Pharma's Current Ratio or its related term are showing as below:

HKSE:09969' s Current Ratio Range Over the Past 10 Years
Min: 0.51   Med: 19.49   Max: 39.18
Current: 4.19

During the past 7 years, InnoCare Pharma's highest Current Ratio was 39.18. The lowest was 0.51. And the median was 19.49.

HKSE:09969's Current Ratio is ranked better than
53.36% of 1548 companies
in the Biotechnology industry
Industry Median: 3.795 vs HKSE:09969: 4.19

InnoCare Pharma Current Ratio Historical Data

The historical data trend for InnoCare Pharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Current Ratio Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 36.68 39.18 19.49 4.48 4.19

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.48 4.39 4.42 4.19 -

Competitive Comparison of InnoCare Pharma's Current Ratio

For the Biotechnology subindustry, InnoCare Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Current Ratio falls into.



InnoCare Pharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

InnoCare Pharma's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=9587.325/2290.366
=4.19

InnoCare Pharma's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=9587.325/2290.366
=4.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (HKSE:09969) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


InnoCare Pharma Current Ratio Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Cui Jisong
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner

InnoCare Pharma (HKSE:09969) Headlines

No Headlines